https://dermfield.com/articles/seppic-triples-natural-extract-capacity-at-french-lons-plant Derm Field en 2026-11-01T02:12:05.407Z Seppic Triples Natural Extract Capacity at French Lons Plant https://dermfield.com/articles/fda-approves-ilumya-for-active-psoriatic-arthritis-in-adults Derm Field en 2026-10-31T05:02:03.983Z FDA Approves ILUMYA for Active Psoriatic Arthritis in Adults https://dermfield.com/articles/melanoma-til-therapy-hits-62-5-response-rate-in-esmo-data Derm Field en 2026-10-30T17:06:08.384Z Melanoma TIL Therapy Hits 62.5% Response Rate in ESMO 2026 Data https://dermfield.com/articles/melanoma-trial-tests-individualized-neoantigen-therapy-at-scale Derm Field en 2026-10-30T16:41:08.336Z Melanoma Trial Tests Individualized Neoantigen Therapy at Scale https://dermfield.com/articles/starboard-extends-median-pfs-to-33-months-in-melanoma Derm Field en 2026-10-30T16:41:08.336Z STARBOARD Extends Median PFS to 33 Months in Melanoma https://dermfield.com/articles/mercury-at-13-200-ppm-found-in-uk-counterfeit-cosmetics-ipo-probe Derm Field en 2026-10-30T15:36:08.279Z Mercury at 13,200 ppm Found in UK Counterfeit Cosmetics: IPO Probe https://dermfield.com/articles/longevity-science-is-redefining-personal-care-ingredient-development Derm Field en 2026-10-30T15:36:08.279Z Longevity Science Is Redefining Personal Care Ingredient Development https://dermfield.com/articles/founder-margo-marrone-reacquires-the-organic-pharmacy-after-decade-under-ganassi Derm Field en 2026-10-30T15:36:08.279Z Founder Margo Marrone Reacquires The Organic Pharmacy After Decade Under Ganassini https://dermfield.com/articles/fda-approves-remibrutinib-as-first-therapy-for-symptomatic-dermographism Derm Field en 2026-10-30T15:36:08.279Z FDA Approves Remibrutinib as First Therapy for Symptomatic Dermographism https://dermfield.com/articles/non-adherence-drives-apparent-acne-treatment-failure-gpwer-says Derm Field en 2026-10-30T13:46:13.305Z Non-adherence drives apparent acne treatment failure, GPwER says https://dermfield.com/articles/p53-activation-with-navtemadlin-boosts-t-cell-killing-of-melanoma Derm Field en 2026-10-30T13:16:08.040Z p53 Activation With Navtemadlin Boosts T-Cell Killing of Melanoma